Northwest Biotherapeutics INC 8-K filings

Northwest Biotherapeutics has entered into a $4.9 million convertible promissory note financing with Yorkville Advisors Global, LP, and a standby equity subscription agreement for up to $50 million.

Northwest Biotherapeutics, Inc. has completed the acquisition of Advent BioServices Ltd., a UK-based CDMO, for approximately $1.9 million plus outstanding payables.

Northwest Biotherapeutics, Inc. has reached a settlement in litigation concerning 2020 option awards, resulting in a $2.25 million payment to the company from insurers and the cancellation of 17% of challenged options.

Northwest Biotherapeutics stockholders approved an increase in authorized common stock, re-elected a director, and ratified executive compensation at their annual meeting.

Northwest Biotherapeutics, Inc. has secured a $5 million convertible promissory note to fund its UK manufacturing facility and operations.

Northwest Biotherapeutics, Inc. has secured a $5.5 million commercial loan from Streeterville Capital, LLC to fund ongoing business operations.

Northwest Biotherapeutics, Inc. has finalized its acquisition of Advent BioServices Ltd., gaining assets and recovering 19 million securities.

Northwest Biotherapeutics, Inc. filed a new Form S-3 shelf registration statement to replace its expiring one, ensuring continuous access to capital markets.

Northwest Biotherapeutics, Inc. announced a settlement in litigation regarding 2020 option awards, resulting in option cancellations and a $2.25 million payment from insurers.

Northwest Biotherapeutics has entered into a $5 million convertible note financing agreement and a standby equity purchase agreement for up to $50 million.

Northwest Biotherapeutics has entered into a $5 million convertible loan agreement with an unrelated shareholder to support ongoing business operations.

Northwest Biotherapeutics is investigating the source of recent social media rumors that coincide with market developments and a pending lawsuit.

Northwest Biotherapeutics successfully held its annual meeting, re-electing directors and ratifying the appointment of its accounting firm, along with prior option awards and executive compensation.

Northwest Biotherapeutics has entered into a stock purchase agreement with SIO Capital Management for $3.25 million to fund ongoing operations.

Northwest Biotherapeutics has entered into an $11.005 million loan agreement with Streeterville Capital, LLC to fund ongoing operations and facility upgrades.

Northwest Biotherapeutics has appointed Pat Sarma as a new Class II director and member of key board committees, effective March 18, 2024.

Northwest Biotherapeutics announces the retirement of director Jerry Jasinowski due to health reasons, effective March 8, 2024.